| Metformin and cancer: new applications for an old drug TV Kourelis, RD Siegel Medical Oncology 29, 1314-1327, 2012 | 394 | 2012 |
| Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death E Muchtar, MA Gertz, SK Kumar, MQ Lacy, D Dingli, FK Buadi, M Grogan, ... Blood, The Journal of the American Society of Hematology 129 (15), 2111-2119, 2017 | 323 | 2017 |
| Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria A Lakshman, SV Rajkumar, FK Buadi, M Binder, MA Gertz, MQ Lacy, ... Blood cancer journal 8 (6), 59, 2018 | 269 | 2018 |
| Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis TV Kourelis, SK Kumar, MA Gertz, MQ Lacy, FK Buadi, SR Hayman, ... Journal of clinical oncology 31 (34), 4319-4324, 2013 | 254 | 2013 |
| Therapy for relapsed multiple myeloma: guidelines from the Mayo stratification for myeloma and risk-adapted therapy D Dingli, S Ailawadhi, PL Bergsagel, FK Buadi, A Dispenzieri, R Fonseca, ... Mayo Clinic Proceedings 92 (4), 578-598, 2017 | 180 | 2017 |
| Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer AS Mansfield, AJ Tafur, CE Wang, TV Kourelis, EM Wysokinska, P Yang Journal of Thrombosis and Haemostasis 14 (9), 1773-1778, 2016 | 148 | 2016 |
| Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement WI Gonsalves, FK Buadi, S Ailawadhi, PL Bergsagel, AA Chanan Khan, ... Bone marrow transplantation 54 (3), 353-367, 2019 | 135 | 2019 |
| Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category E Muchtar, A Dispenzieri, SK Kumar, RP Ketterling, D Dingli, MQ Lacy, ... Leukemia 31 (7), 1562-1569, 2017 | 134 | 2017 |
| Clarifying immunoglobulin gene usage in systemic and localized immunoglobulin light-chain amyloidosis by mass spectrometry TV Kourelis, S Dasari, JD Theis, M Ramirez-Alvarado, PJ Kurtin, MA Gertz, ... Blood, The Journal of the American Society of Hematology 129 (3), 299-306, 2017 | 133 | 2017 |
| A modern primer on light chain amyloidosis in 592 patients with mass spectrometry–verified typing E Muchtar, MA Gertz, RA Kyle, MQ Lacy, D Dingli, N Leung, FK Buadi, ... Mayo Clinic Proceedings 94 (3), 472-483, 2019 | 132 | 2019 |
| Stem cell transplantation for light chain amyloidosis: decreased early mortality over time MH Sidiqi, MA Aljama, FK Buadi, RM Warsame, MQ Lacy, A Dispenzieri, ... Journal of Clinical Oncology 36 (13), 1323-1329, 2018 | 127 | 2018 |
| Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response N Abdallah, SV Rajkumar, P Greipp, P Kapoor, MA Gertz, A Dispenzieri, ... Blood cancer journal 10 (8), 82, 2020 | 117 | 2020 |
| Outcomes of patients with renal monoclonal immunoglobulin deposition disease TV Kourelis, SH Nasr, A Dispenzieri, SK Kumar, MA Gertz, FC Fervenza, ... American journal of hematology 91 (11), 1123-1128, 2016 | 110 | 2016 |
| Presentation and outcomes of localized immunoglobulin light chain amyloidosis: the Mayo Clinic experience TV Kourelis, RA Kyle, D Dingli, FK Buadi, SK Kumar, MA Gertz, MQ Lacy, ... Mayo Clinic proceedings 92 (6), 908-917, 2017 | 102 | 2017 |
| Clinical heterogeneity of the VEXAS syndrome: a case series MJ Koster, T Kourelis, KK Reichard, TA Kermani, DB Beck, DO Cardona, ... Mayo Clinic Proceedings 96 (10), 2653-2659, 2021 | 98 | 2021 |
| Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria E Muchtar, A Dispenzieri, N Leung, MQ Lacy, FK Buadi, D Dingli, ... Leukemia 32 (10), 2240-2249, 2018 | 97 | 2018 |
| Long‐term outcome of patients with POEMS syndrome: an update of the Mayo Clinic experience TV Kourelis, FK Buadi, SK Kumar, MA Gertz, MQ Lacy, D Dingli, RS Go, ... American journal of hematology 91 (6), 585-589, 2016 | 91 | 2016 |
| Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis JP Abeykoon, S Zanwar, A Dispenzieri, MA Gertz, N Leung, T Kourelis, ... Leukemia 33 (2), 531-536, 2019 | 90 | 2019 |
| Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia J Paludo, JP Abeykoon, A Shreders, SM Ansell, S Kumar, S Ailawadhi, ... Annals of hematology 97, 1417-1425, 2018 | 90 | 2018 |
| Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression WI Gonsalves, SV Rajkumar, A Dispenzieri, D Dingli, MM Timm, ... Leukemia 31 (1), 130-135, 2017 | 89 | 2017 |
Wilson I GonsalvesAssociate Professor of Medicine, Mayo Clinic, Rochester MNEmail verificata su mayo.edu
